City of Portland targeted in $6.7 million fraud scheme
PORTLAND, Ore. () — City of Portland officials said they are working with local and federal law enforcement agencies to investigate a $6.7 million fraud scheme.
About $6.7 million set aside for use in the Bull Run Filtration Project was redirected due to the fraudulent activity, according to .
Unhappy homeowners target Habitat for Humanity lunch
Initially, the city filed a lawsuit against a New York law firm whose account held the deposited funds, Portland officials said. However, the lawsuit will be dropped after 'the law firm provided information supporting that they were also a victim.'
'The law firm has cooperated with the City of Portland and others to facilitate securing the funds,' the City of Portland said in a press release. 'The funds are currently in the custody of the U.S. Marshals Service.'
The city said it is taking the matter seriously, will work to hold others accountable and is committed to transparency as the investigation continues. They also said the information that they can share about the case may be limited as the investigation is underway.
According to the original lawsuit, a man going by the alias John Lisman allegedly fraudulently presented himself as a vendor for the Bull Run Filtration Project and manipulated city officials into rerouting the $6.7 million.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
15 minutes ago
- Business Upturn
Krispy Kreme, Inc. Class Action: Levi & Korsinsky Reminds Krispy Kreme, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 15, 2025
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Krispy Kreme, Inc. ('Krispy Kreme, Inc.' or the 'Company') (NASDAQ: DNUT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Krispy Kreme, Inc. investors who were adversely affected by alleged securities fraud between February 25, 2025 and May 7, 2025. Follow the link below to get more information and be contacted by a member of our team: Krispy Kreme, Inc. Lawsuit Submission Form DNUT investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) demand for Krispy Kreme products declined materially at McDonald's locations after the initial marketing launch; (2) demand at McDonald's locations was a driver of declining average sales per door per week; (3) the partnership with McDonald's was not profitable; (4) the foregoing posed a substantial risk to maintaining the partnership with McDonald's; (5) as a result, the Company would pause expansion into new McDonald's locations; and (6) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. WHAT'S NEXT? If you suffered a loss in Krispy Kreme, Inc. during the relevant time frame, you have until July 15, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. CONTACT:Levi & Korsinsky, LLP Joseph E. Levi, Korsinsky, Esq.33 Whitehall Street, 17th FloorNew York, NY 10004 [email protected] Tel: (212) 363-7500Fax: (212) 363-7171
Yahoo
34 minutes ago
- Yahoo
Should You Invest in Intuitive Surgical (ISRG) Based on Bullish Wall Street Views?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important? Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Intuitive Surgical, Inc. (ISRG). Intuitive Surgical currently has an average brokerage recommendation (ABR) of 1.62, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 29 brokerage firms. An ABR of 1.62 approximates between Strong Buy and Buy. Of the 29 recommendations that derive the current ABR, 20 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 69% and 6.9% of all recommendations. Check price target & stock forecast for Intuitive Surgical here>>> While the ABR calls for buying Intuitive Surgical, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential. Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations. This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements. Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision. Although both Zacks Rank and ABR are displayed in a range of 1--5, they are different measures altogether. The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5. Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide. On the other hand, earnings estimate revisions are at the core of the Zacks Rank. And empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks. There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices. In terms of earnings estimate revisions for Intuitive Surgical, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at $7.84. Analysts' steady views regarding the company's earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Intuitive Surgical. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for Intuitive Surgical. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
34 minutes ago
- Yahoo
Are Computer and Technology Stocks Lagging Lam Research (LRCX) This Year?
The Computer and Technology group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Lam Research (LRCX) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Computer and Technology sector should help us answer this question. Lam Research is one of 608 individual stocks in the Computer and Technology sector. Collectively, these companies sit at #7 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Lam Research is currently sporting a Zacks Rank of #2 (Buy). Within the past quarter, the Zacks Consensus Estimate for LRCX's full-year earnings has moved 7.4% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive. Our latest available data shows that LRCX has returned about 22.3% since the start of the calendar year. At the same time, Computer and Technology stocks have gained an average of 1.8%. This means that Lam Research is performing better than its sector in terms of year-to-date returns. Another Computer and Technology stock, which has outperformed the sector so far this year, is Couchbase, Inc. (BASE). The stock has returned 27.4% year-to-date. Over the past three months, Couchbase, Inc.'s consensus EPS estimate for the current year has increased 6.6%. The stock currently has a Zacks Rank #2 (Buy). Looking more specifically, Lam Research belongs to the Electronics - Semiconductors industry, a group that includes 45 individual stocks and currently sits at #82 in the Zacks Industry Rank. On average, stocks in this group have gained 3% this year, meaning that LRCX is performing better in terms of year-to-date returns. Couchbase, Inc. however, belongs to the Internet - Software industry. Currently, this 169-stock industry is ranked #54. The industry has moved +13.2% so far this year. Lam Research and Couchbase, Inc. could continue their solid performance, so investors interested in Computer and Technology stocks should continue to pay close attention to these stocks. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Lam Research Corporation (LRCX) : Free Stock Analysis Report Couchbase, Inc. (BASE) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
